unknown
Stage
About
Breakpoint Therapeutics GmbH is a biotechnology company that discovers and develops small-molecule cancer therapies targeting DNA damage response (DDR) pathways. Its pipeline includes preclinical programs such as polymerase theta (POLQ) inhibitors aimed at treating oncology indications.
Explore Breakpoint Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.